Imbio PHA (4.0.0) vs Eko Low Ejection Fraction Tool (ELEFT)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Imbio (a subsidiary of 4DMedical)
VS

AI Verdict

Tool A is designed for post-imaging analysis, leveraging CT pulmonary angiogram scans to assess right ventricular dilation for conditions such as pulmonary embolism and hypertension. Conversely, Tool B integrates with digital stethoscopes to analyze ECG and heart sound recordings, aiding in the early detection of low ejection fraction during routine physical exams. While both are FDA-cleared cardiology AI tools, they operate on different data types and target distinct stages and aspects of cardiac assessment.

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA (4.0.0) if your clinical workflow involves analyzing CT pulmonary angiogram (CTPA) scans and you require automated, precise measurements of cardiac structures. This tool is ideal for radiologists and cardiologists needing to assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension, integrating seamlessly with existing DICOM workflows for detailed post-imaging analysis.

View Imbio PHA (4.0.0) →

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if you are a clinician performing routine physical exams and need a rapid, non-invasive screening tool for early detection of low ejection fraction. This AI algorithm, integrated with Eko digital stethoscopes, is best suited for primary care, family medicine, or cardiology settings where quick identification of potential heart failure risk during a patient encounter is paramount.

View Eko Low Ejection Fraction Tool (ELEFT) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Imbio PHA (4.0.0) Eko Low Ejection Fraction Tool (ELEFT)
Deployment Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). Unknown
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

Eko ELEFT offers superior usability for a broader range of clinicians due to its rapid, non-invasive screening capability during routine physical exams, providing results in approximately 15 seconds. While Imbio PHA integrates well into existing radiology workflows, ELEFT's point-of-care application with a familiar device like a stethoscope makes it highly accessible for immediate clinical decision-making.

Clinical Value

Tie

Both tools are FDA-cleared and provide significant clinical value in their respective domains. Imbio PHA offers detailed quantitative diagnostic information from CTPA scans for pulmonary embolism and hypertension, while Eko ELEFT enables crucial early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. Their impact is high, but in different stages and contexts of patient care.

Pricing & Value

Tie

Neither product provides transparent pricing, with both requiring direct contact for specific quotes. Tool B is explicitly stated to be part of an 'enterprise solution' platform, which might imply a bundled cost, but without concrete pricing details for either, a direct comparison of their financial value is not feasible.

Enterprise Readiness

Imbio PHA (4.0.0)

Imbio PHA demonstrates greater enterprise readiness by offering flexible deployment options including cloud, on-premise, or via partners, accommodating diverse IT infrastructures and data governance needs. Although Eko ELEFT is part of an enterprise platform and is HIPAA compliant, its cloud-based deployment integrated with specific hardware may be less adaptable for some large organizations compared to Imbio's broader options.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

Eko ELEFT presents a more disruptive innovation by integrating AI-powered diagnostics with a traditional physical exam tool, the digital stethoscope, for real-time, non-invasive screening at the point of care. While Imbio PHA innovates by automating complex measurements from existing imaging, ELEFT's approach expands diagnostic capabilities into routine patient interactions in a novel way.

Support & Docs

Imbio PHA (4.0.0)

Imbio provides clear and direct support channels, including phone and email support, and an online case submission form, explicitly stating that user manuals and product documentation are available upon request. While Eko Health offers a help center and various contact methods, some customer feedback suggests potential inconsistencies in their support responsiveness.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Imbio PHA (4.0.0) Eko Low Ejection Fraction Tool (ELEFT)
Primary Clinical Focus Assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. Aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure.
Input Modality/Data CT pulmonary angiogram (CTPA) scans. ECG and heart sound recordings from Eko digital stethoscopes.
Key Measurements/Detection Automated measurement of right and left ventricle diameters, automated measurement of main pulmonary artery and aorta diameters, calculates RV/LV and PA/Ao ratios. AI-powered low ejection fraction detection.
Target Medical Specialties Cardiology, Pulmonology, Radiology. Cardiology, Family Medicine, Internal Medicine.
Result Output Annotated DICOM images, summary reports in PDF format. Not specified
Processing Time Rapid, fully-automated assessment (typically in minutes). Approximately 15 seconds.

Videos

Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Eko Low Ejection Fraction Tool (ELEFT).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Imbio PHA (Tool A) is designed to automatically measure cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation, aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension. The Eko Low Ejection Fraction Tool (ELEFT) (Tool B) is an AI algorithm integrated with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Imbio PHA (Tool A) processes medical images, specifically CT pulmonary angiogram (CTPA) scans, utilizing artificial intelligence algorithms for anatomical identification and measurement. ELEFT (Tool B) analyzes ECG and heart sound recordings, which are captured through its integration with FDA-cleared Eko digital stethoscopes.
Imbio PHA (Tool A) is relevant for Cardiology, Pulmonology, and Radiology specialties. ELEFT (Tool B) is designed for use in Cardiology, Family Medicine, and Internal Medicine.
Imbio PHA (Tool A) provides automated measurements of right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios, generating annotated DICOM images and PDF summary reports. ELEFT (Tool B) provides AI-powered low ejection fraction detection results, aiding in the early identification of heart failure risk.
Imbio PHA (Tool A) offers rapid, fully-automated assessment, typically providing results in minutes. ELEFT (Tool B) provides its results in approximately 15 seconds.

Backers

Who funded each tool's parent company.

Eko Low Ejection Fraction Tool (ELEFT)

AI Tool Finder
AI-powered search. Results may not be comprehensive.